Mendus (IMMU.ST) Stock Analysis & AI Equity Report
Mendus (IMMU.ST) overview
Mendus (IMMU.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Mendus reported revenue of SEK 0m and operating profit of SEK -120m; the year-end share price was 5.60 SEK and market capitalisation was SEK 292m. Mendus is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Mendus's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Mendus
Mendus AB is a Swedish biopharmaceutical company developing immunotherapies for cancer, with a focus on preventing tumor recurrence and supporting longer disease-free survival. Its lead program is vididencel, a cell-based therapy being advanced in myeloid blood cancers, including chronic myeloid leukemia, alongside clinical development and manufacturing activities.
Generate the Mendus report
Mendus is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Mendus and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Mendus
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.